CHRNA4
Neuronal acetylcholine receptor subunit alpha-4
As of the edition of 20 October 2026, CHRNA4 (neuronal acetylcholine receptor subunit alpha-4, UniProt P43681) has 12 drugs tested at it and 16 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43681
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 12
- Disease areas
- Mental health; Chemically induced; Nervous system; Cancer; Lungs and airways; Urinary and reproductive; Immune system; Infections
- Registered trials of its drugs
- 708
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 6 |
| Stopped | 3 |
| Total | 12 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Nicotine | Marketed | Phase 4 | none listed |
| Varenicline | Marketed | Phase 4 | none listed |
| Cytisinicline | Marketed | Phase 4 | none listed |
| Dexmecamylamine | Went quiet | Phase 3 | none listed |
| Ispronicline | Went quiet | Phase 2 | none listed |
| AZD1446 | Stopped | Phase 2 | none listed |
| Pozanicline | Stopped | Phase 2 | none listed |
| Sofinicline | Went quiet | Phase 2 | none listed |
| CP-601927 | Stopped | Phase 2 | none listed |
| Dianicline | Went quiet | Phase 3 | none listed |
| Simpinicline | Went quiet | Phase 2 | none listed |
| TC-2216 | Went quiet | Phase 1 | none listed |
12 of 12 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 11 |
| Total on the list | 16 |
The other 13 companies at CHRNA4
In the product16 companies in all; 13 are not named here, and no score is.
See the 16 companies at CHRNA4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.